BiotechTube

camrelizumab& apatinib

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Dec 17, 2021 → Feb 11, 2024

NCT ID
NCT05550025

About camrelizumab& apatinib

camrelizumab& apatinib is a phase 2 stage product being developed by Sun Pharmaceutical for Hepatocellular Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05550025. Target conditions include Hepatocellular Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05550025Phase 2UNKNOWN

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
25
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
Ramucirumab + PlaceboEli LillyPhase 3
77
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
77
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
33
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
52
Tivantinib + PlaceboDaiichi SankyoPhase 3
77
OSI-906 + PlaceboAstellas PharmaPhase 2
52
Enzalutamide + PlaceboAstellas PharmaPhase 2
52
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
33
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
33
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
52
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
52
LenvatinibEisaiPre-clinical
23
Lenvatinib PillEisaiPhase 2
52
Sorafenib + SorafenibEisaiPhase 1/2
41
LenvatinibEisaiPhase 2
52
Lenvatinib + NivolumabEisaiPhase 2
52
H3B-6527EisaiPhase 1
33

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85